|
Jun 24
|
BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT
|
|
May 23
|
What Makes Relay Therapeutics (RLAY) a New Buy Stock
|
|
May 13
|
Relay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy Now
|
|
May 7
|
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory
|
|
Apr 20
|
Relay Therapeutics (RLAY): The Most Promising Penny Stock According to Analysts
|
|
Feb 24
|
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
|
|
Feb 19
|
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
|
|
Dec 30
|
Is Relay Therapeutics (RLAY) the Best Biotech Penny Stock to Invest in Now?
|
|
Aug 6
|
Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
|
|
Jul 30
|
Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
|
|
Jul 24
|
We're Not Very Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate
|
|
Jun 6
|
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
|
|
Jun 5
|
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
|
|
May 13
|
Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
|
|
May 4
|
Relay Therapeutics First Quarter 2024 Earnings: Beats Expectations
|
|
May 2
|
Relay Therapeutics Outperforms Revenue Expectations in Q1 2024
|
|
May 2
|
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 2
|
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
|
|
Apr 25
|
Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
|
|
Apr 11
|
Relay Therapeutics to Participate in Upcoming Investor Conferences
|